Home
Podcasts
Biotech Business with Fexingo: Life Sciences Startups, Drug Discovery, and FDA Approvals
Biotech Business with Fexingo: Life Sciences Startups, Drug Discovery, and FDA Approvals
Lucas and Luna explore the world of biotechnology startups, dissecting the science, business models, and regulatory paths of companies from Moderna to CRISPR spinouts. They analyze clinical trial phases, patent cliffs, and burn rates while focusing on the human stories behind drug discovery. The podcast aims to help listeners understand biotech 10-Ks, Phase II readouts, and distinguish genuine breakthroughs from stock promotions.
Episodes
The Biotech Valuation Trap
Biotech startups often hit a wall not because their science fails, but because they misprice the bridge to commercialization. Lucas and Luna examine how the 'Valuation Gap' between late-stage venture capital and public market expectations creates a death spiral for promising drugs. They break down why recent FDA approvals have led to stock drops, the hidden costs of Phase Three trials, and why sma
How Biotech Startups Navigate Regulatory Moats
We look at how emerging biotech firms use regulatory strategy as a competitive weapon rather than a compliance burden. With the FDA’s Real-World Evidence framework gaining traction by October 2026, startups are leveraging patient data to accelerate approvals. We explore specific case studies of companies that turned clinical trial constraints into strategic advantages, avoiding common pitfalls in
How Biotech Startups Navigate Patent Thickets
We examine the strategic pivot of a leading gene therapy firm as it faces an expanding web of overlapping intellectual property claims. Lucas and Luna break down why traditional patent protection is no longer enough for life sciences startups in late-stage development, and how companies are using regulatory exclusivity and novel licensing structures to protect their pipeline assets. This episode e
Biotech Startups And The Regulatory Moat
We explore how early-stage life science companies are building defensible competitive advantages not through proprietary algorithms, but through deep regulatory strategy. Using the FDA's Breakthrough Therapy designation as a lens, we examine why some biotech firms accelerate approval timelines while others stall in clinical death valleys. Lucas and Luna break down the economics of regulatory moats
How Biotech Startups Win Big Pharma Partnerships
Most biotech founders think the hard part is discovering a molecule. The real bottleneck is convincing large pharmaceutical companies to buy in before Phase Two data exists. In this episode, we examine how early-stage life sciences startups structure value-acknowledgment deals and milestone payments to bridge the gap between lab results and commercial scale. We look at why big pharma prefers licen
The Biotech Exit Premium Puzzle
We look at why biotech startups are selling for less than their R&D costs suggest, using a specific recent deal structure to explain the shift from pipeline value to cash flow reality. Lucas and Luna break down how investor patience has evaporated since early 2024, leaving founders with a choice between dilution or discount. We examine one mid-cap company that pivoted its go-to-market strategy to
The Biotech Lab Rat Economy
We explore how biotech startups are shifting from the expensive, slow traditional animal testing model to high-throughput organ-on-a-chip platforms. Using a specific case of a cardiovascular drug candidate that failed in Phase Two but showed promising safety signals in human cell models, we examine why this pivot matters for de-risking clinical trials and attracting venture capital in late October
How Biotech Startups Fix Their Own Broken Supply Chains
We drill into the operational reality of vertical integration in life sciences. Lucas and Luna examine why startups are no longer outsourcing manufacturing to third-party contract organizations but building internal capacity instead. We look at the specific capital trade-offs, the technical hurdles of scaling bioreactors, and the strategic advantage of controlling your own production from Phase Tw
How Biotech Startups Monetize Patient Data
We examine the emerging revenue model where biotech startups license anonymized real-world patient data rather than selling drug assets alone. Lucas and Luna break down how companies like Flatiron Health have shifted from clinical trial support to independent data analytics firms, and what this means for startup valuation in October twenty twenty-six.
#BiotechStartups #RealWorldData #PatientDataM
Biotech Startups Navigating The Clinical Trial Death Valley
Episode 206 explores the 'Clinical Trial Death Valley' where promising biotech candidates stall not because of bad science, but due to operational bottlenecks and misaligned incentives. Lucas and Luna dissect how startups are leveraging decentralized trial models and real-world evidence to bridge the gap between Phase One success and regulatory approval. We examine specific data points on patient
The Hidden Cost of Biotech Clinical Trials
We explore how life sciences startups are navigating the clinical trial death valley by leveraging decentralized technology and real-world data to cut costs. This episode examines specific strategies for reducing patient attrition and streamlining site selection, offering actionable insights for founders and investors in the biotech sector.
#BiotechStartups #ClinicalTrials #DrugDiscovery #FDAAppr
Biotech Startups And The Valuation Reset
We look at how biotech founders are navigating the post-2021 capital correction. With interest rates still elevated in October two thousand twenty-six, early-stage deals have shifted from growth-at-all-costs to path-to-profitability. We examine a specific case study of a gene therapy startup that pivoted its clinical strategy to extend runway without diluting shareholders. Lucas and Luna break dow
The Clinical Trial Death Valley Problem
We talk about the specific financial trap known as 'Clinical Trial Death Valley' that traps promising biotech startups between Phase One success and Phase Three funding. Using the case of a hypothetical but representative gene therapy firm, we break down why capital markets are punishing these companies right now in October two thousand twenty-six, and how venture debt and strategic partnerships a
Why Biotech Startups Fail At Scale
We examine the specific operational gap that kills promising biotech companies after their initial discovery phase. Using a hypothetical mid-stage gene therapy firm as our anchor, we break down why scaling manufacturing and clinical operations is fundamentally different from early research. We discuss the hidden costs of quality control, the talent war for experienced plant managers, and how ventu
How Biotech Startups Use Real World Data To Speed Trials
Episode 201 explores how life sciences startups are bypassing traditional clinical trial delays by integrating real world data into early development. We examine the specific mechanics of using electronic health records and wearable device telemetry to de-risk Phase Two decisions before committing to expensive randomized controlled trials. Lucas and Luna break down a concrete case where a small bi
The Biotech Capital Crunch And The Rise Of Venture Debt
With the venture capital market tightening in September 2026, early-stage biotech startups are facing a harsh new reality. We explore how companies like Arbutus Biopharma and smaller peers are pivoting from traditional equity financing to venture debt instruments to extend their runway. Lucas and Luna break down the mechanics of bridge loans, the hidden costs of dilution avoidance, and why the cur
Why Biotech Startups Are Betting on Rare Diseases
We examine how small-cap biotech firms are shifting capital from crowded oncology targets to ultra-rare genetic disorders. Lucas and Luna break down the economics of orphan drug designations, the specific regulatory incentives driving this pivot, and why the market is finally rewarding focused science over broad platform hype. We look at a recent case study of a startup that secured FDA approval f
The Silent Killer of Biotech Deals
We break down the critical, often overlooked bottleneck in biotech startups: the transition from discovery to clinical manufacturing. Lucas and Luna examine why most promising drug candidates fail not because of efficacy, but because they cannot be scaled for human trials. We look at the specific engineering challenges of cell therapy production, the rise of continuous processing, and how early-st
How AI Is Rewriting Drug Discovery Pipelines
We look at how deep learning models are shifting biotech from trial-and-error to predictive design. Using AlphaFold and modern generative chemistry as anchors, we examine the real impact on discovery timelines, the data quality problem that still haunts startups, and what this means for valuation in late September 2026. It is not magic, it is a new layer of infrastructure.
#BiotechInnovation #Art
The Hidden Cost of Biotech Clinical Trials
Biotech startups are burning through cash at unprecedented rates, but the real bottleneck isn't just funding—it's the operational friction in clinical trials. We break down how leading life sciences companies are using digital health technologies and decentralized trial models to cut patient recruitment time by nearly half. Lucas and Luna explore why this shift matters for drug discovery timelines
The Biotech Supply Chain Black Box
We talk to operators about the hidden bottleneck in drug development: cell and gene therapy manufacturing. With global demand for mRNA vaccines and CAR-T treatments outpacing capacity, startups are betting on modular, single-use bioreactors to scale faster than traditional steel-tank facilities. We examine why this shift matters for patient access and how it changes the risk profile for early-stag
Biotech Startups Mastering Clinical Trial De-Risking
In this episode of Biotech Business with Fexingo, Lucas and Luna examine how early-stage life sciences companies are shifting their strategy from pure discovery to clinical de-risking. We look at the specific mechanics of using real-world evidence and adaptive trial designs to secure Series B funding in today's valuation environment. The conversation centers on a recent deal structure involving a
How Biotech Startups Use Real-World Data To Speed Trials
Biotech startups are bypassing traditional recruitment bottlenecks by integrating real-world data from wearables and electronic health records into clinical trials. Lucas and Luna examine how companies like Tempus and Flatiron Health are turning passive patient data into active trial assets, reducing enrollment time by half while raising questions about privacy and regulatory acceptance at the FDA
Biotech Startups And The CMO Bottleneck
In this episode of Biotech Business with Fexingo, Lucas and Luna explore the critical manufacturing crisis facing life sciences startups. With clinical trials failing at unprecedented rates in the current market environment, the bottleneck is no longer discovery—it's scale-up. We examine how contract manufacturing organizations are struggling to meet demand, the hidden costs of delayed timelines,
The Biotech Patent Cliff And The Race To License First
With the foundational CRISPR patents facing expiration in late 2026, Lucas and Luna break down how life sciences startups are pivoting from proprietary moats to open-access licensing models. They examine the specific financial mechanics of this shift, using a hypothetical but realistic mid-stage gene therapy firm as a case study to show why speed-to-market now outweighs exclusive IP control. This
Biotech Startups Navigating The Valuation Winter
In this episode, we examine the structural shift in biotech financing as venture capital tightens its grip on early-stage drug discovery. With interest rates holding steady into September of two thousand twenty-six, startups are forced to choose between dilutive equity raises and expensive venture debt. We break down how companies like Intellia Therapeutics and Beam Therapeutics are adjusting thei
How Biotech Startups Are Solving The Protein Degradation Problem
We’re looking at the operational reality of protein degraders, specifically PROTACs, in early-stage biotech. While the science is proven, the manufacturing bottleneck remains severe. Lucas and Luna break down why scaling production for these binary molecules is so different from traditional small-molecule drugs, focusing on the specific supply chain constraints facing startups like Arvinas and C4
Biotech Startups And The CMO Bottleneck
While AI and gene editing grab headlines, biotech startups face a silent killer: the lack of skilled Contract Manufacturing Organizations. We explore how the shortage of CMO capacity is delaying approvals, inflating costs, and forcing early-stage companies to pivot their business models entirely in late 2026.
#BiotechStartups #ContractManufacturing #CMOBottleneck #DrugDevelopment #FDAApprovals #V
Biotech Startups Mastering In Vivo Gene Delivery
In vivo gene editing promises to cure disease by fixing DNA inside the body, but delivery remains the bottleneck. We examine how startups are solving this with lipid nanoparticles and viral vectors, using specific examples from recent clinical trials in September 2026. Learn why getting the therapeutic payload to the right cell is harder than designing the edit itself.
#BiotechStartups #InVivoGen
Biotech Startups Mastering In Vivo Gene Delivery
This episode explores how biotech startups are bypassing traditional drug delivery bottlenecks by engineering viral vectors for in vivo gene therapy. We examine the specific mechanics of lipid nanoparticles and adeno-associated virus capsids, focusing on the recent breakthroughs in tissue targeting that allow treatments to reach the liver, eye, and brain without systemic toxicity. Lucas and Luna d
How Biotech Startups Are Winning With Platform Models
We look at how emerging biotech firms are shifting from single-product bets to reusable discovery platforms, using the specific case of Recursion Pharmaceuticals and its partnership with Merck. Lucas and Luna break down why investors are finally rewarding platform durability over binary trial outcomes, and what this means for drug pricing and pipeline depth in late September twenty twenty six.
#B
The Quiet Rise of In Vivo Gene Editing
We explore how in vivo gene editing is shifting from laboratory curiosity to commercial reality. While earlier episodes covered base editing and CRISPR in general, this conversation focuses on the logistical and biological hurdles of delivering genetic cargo directly into human organs like the liver and heart. We look at lipid nanoparticles as the primary delivery vehicle, examining why they work
How Biotech Startups Are Winning With Platform Models
Most biotech startups fail because they bet on a single molecule instead of a reusable engine. This episode explores how platform technologies like CRISPR delivery systems and continuous manufacturing are changing the economics of drug discovery. We look at specific examples of companies that built scalable infrastructure rather than just one-off assets, and why investors are shifting capital from
The Biotech Supply Chain Bottleneck
In this episode of Biotech Business, Lucas and Luna dissect the hidden crisis in life sciences: the critical shortage of single-use bioreactor bags. With global demand outpacing supply, startups are facing lead times of up to six months for essential consumables. We explore how companies like Sartorius and Merck KGaA are expanding capacity, why secondary suppliers are struggling with quality contr
How Biotech Startups Are Solving The Protein Degradation Problem
We dive into the mechanics and economics of molecular glues and PROTACs, exploring how startups are moving beyond traditional small molecules to selectively tag proteins for destruction. We look at specific clinical progress in targeting previously undruggable disease drivers, the unique manufacturing hurdles of complex biologics, and why this technology is reshaping venture capital valuations in
Biotech Startups Navigating The Valuation Winter
In this episode of Biotech Business, Lucas and Luna dissect the structural shift in life sciences financing as September 2026 arrives. With venture capital drying up for early-stage discovery, startups are pivoting from speculative moonshots to asset-light partnerships and strategic mergers. We examine how companies like Gilead Sciences and Merck are acquiring promising pipelines instead of fundin
The Biotech Valuation Winter And The Rise Of Venture Debt
In September 2026, the biotech sector is navigating a sharp divergence between clinical success and capital access. While regulatory approvals for novel therapies continue at a steady clip, traditional venture equity has grown scarce and expensive. This episode examines how startups are pivoting to venture debt and milestone-based financing to extend their runway without diluting early shareholder
Why Biotech Patents Are Becoming a Nightmare
This episode examines the growing legal and financial crisis in life sciences: the patent cliff. With major blockbuster drugs facing expiration, startups are struggling to secure new intellectual property protection for novel mechanisms like targeted protein degradation and next-generation gene therapies. We explore how the shift from molecule-first to mechanism-first R&D is clashing with outdated
How Biotech Startups Use Organoids for Drug Testing
Episode 177 of Biotech Business with Fexingo explores how organoids are replacing traditional animal models in early-stage drug discovery. Lucas and Luna discuss the specific advantages of three-dimensional cell cultures, including patient-specific disease modeling and reduced reliance on rodent trials. They examine real-world applications in neurology and oncology, highlighting why this shift mat
How Biotech Startups Use Gene Editing for Rare Diseases
We look at the specific mechanics of base editing and prime editing in early-stage biotech, using Vertex Pharmaceuticals as a durable example of how precise genetic fixes are turning previously untreatable conditions into manageable ones. The conversation explores why these tools matter more than broad CRISPR screens for rare disease patients, the regulatory hurdles facing FDA approvals, and the e
Biotech Startups Tackle Drug Development Through AI Simulation
We look at how computational biology is reshaping the earliest stages of drug discovery, focusing on the shift from wet-lab screening to in silico modeling. With Lucas and Luna, we examine why this matters for pipeline efficiency, the specific role of generative AI in protein design, and what investors should watch for as these startups move from simulation to clinical reality. This is a deep dive
The Hidden Cost of Biotech Clinical Trial Failures
Every year, biotech startups spend billions on clinical trials that ultimately fail to prove their drugs work. In this episode of Biotech Business, Lucas and Luna break down the specific financial mechanics behind these failures, focusing on the concept of 'trial inflation' and how early-phase data gaps lead to catastrophic late-stage losses. We examine a hypothetical but realistic case study of a
How Biotech Startups Use Synthetic Biology for Sustainable Materials
This episode explores how synthetic biology startups are moving beyond medicine to create sustainable industrial materials. We examine the specific case of MycoWorks, which uses fungal mycelium to grow leather alternatives that compete with traditional tanning processes. Lucas and Luna discuss the economics of bio-fabrication, the energy savings compared to animal agriculture, and the regulatory h
How Biotech Startups Use Protein Degraders to Target Disease
In this episode, Lucas and Luna dive into the world of targeted protein degradation, a technique that's reshaping how biotech startups approach drug discovery. Instead of just blocking a disease-causing protein, these degraders, like PROTACs and molecular glues, tag it for the cell's own recycling system. Lucas explains the science with a concrete example: a protein called ARV-110, developed by Ar
How Biotech Startups Use AI to Predict Drug Toxicity
Lucas and Luna explore how biotech startups are using artificial intelligence to predict drug toxicity earlier in development, potentially saving billions and avoiding late-stage failures. They discuss the limitations of animal models, the rise of in silico toxicology, and a specific case where AI flagged a cardiotoxicity risk that traditional methods missed. The episode highlights the balance bet
How Biotech Startups Use AlphaFold for Protein Folding
In this episode, Lucas and Luna explore how biotech startups are leveraging AlphaFold, the AI system for protein structure prediction, to accelerate drug discovery. They discuss the breakthrough moment in 2020 when AlphaFold solved the protein folding problem, the subsequent release of the AlphaFold Protein Structure Database with over 200 million predicted structures, and how startups are now usi
How Biotech Startups Use AI to Design Better Antibodies
In this episode of Biotech Business, Lucas and Luna explore how startups are using artificial intelligence to design antibodies that bind more precisely to their targets. They discuss the shift from traditional hybridoma screening to computational design, highlighting companies like AbCellera and IONTAS, and explain how AI reduces the trial-and-error in early drug discovery. Learn about the concep
Biotech Startups Turn to Microbiome Drugs for Metabolic Disease
In this episode of Biotech Business, Lucas and Luna explore how biotech startups are engineering the human microbiome to treat metabolic diseases like type 2 diabetes and obesity. They focus on the case of a startup developing a live biotherapeutic product that targets a specific gut bacterium linked to insulin sensitivity. The conversation covers the science behind microbiome therapies, the regul
Biotech Startups Use Wearables to Revolutionize Clinical Trials
In this episode of Biotech Business with Fexingo, Lucas and Luna explore how biotech startups are leveraging wearable devices to transform clinical trials. They dive into the use of Apple Watches and Fitbits for continuous health monitoring, focusing on how these devices enable remote data collection and improve patient engagement. The discussion highlights a case study of a Parkinson's disease tr
How Biotech Startups Use mRNA Vaccines Beyond COVID
In this episode of Biotech Business with Fexingo, Lucas and Luna explore how biotech startups are applying mRNA technology beyond COVID-19 vaccines. They dive into the story of Moderna's early bet on mRNA and how startups are now targeting cancer, rare diseases, and even personalized therapies. The conversation covers the science of lipid nanoparticles, the business challenges of scaling manufactu
How Biotech Startups Use AI to Design Clinical Trials
Episode 165 of Biotech Business with Fexingo digs into a quiet revolution: AI-driven clinical trial design. Lucas and Luna break down how startups are using machine learning to pick the right patients, predict trial outcomes, and cut years off drug development. They walk through a recent example where an AI-designed trial for a rare oncology drug hit its endpoint in half the expected time, and dis
How Biotech Startups Use Base Editing for Precision Medicine
In episode 164 of Biotech Business with Fexingo, Lucas and Luna explore how biotech startups are leveraging base editing, a precise gene-editing technique that swaps single DNA letters without cutting the double helix. They trace the journey from lab discovery to clinical application, focusing on a specific startup that has moved into human trials. The hosts break down the science in plain English
How Biotech Startups Are Using Cryo-Electron Microscopy
In this episode of Biotech Business, Lucas and Luna explore the growing use of cryo-electron microscopy in biotech startups, focusing on how this Nobel-winning technology has become a practical tool for drug discovery. They begin with a 2025 study where researchers captured the structure of a key cancer protein at near-atomic resolution, a feat unthinkable a decade ago. Lucas explains the shift fr
How Biotech Startups Use Spatial Transcriptomics
This episode of Biotech Business explores how startups are using spatial transcriptomics to map gene activity directly inside tissue, revealing the cellular geography of disease. Lucas and Luna break down the technology — from imaging-based methods like MERFISH to sequencing-based platforms — and discuss how it's reshaping drug discovery, from identifying novel targets to stratifying patients for
How Biotech Startups Use CRISPR Screens to Find New Drug Targets
In episode 161, Lucas and Luna dive into the world of CRISPR screens — a high-throughput method that lets biotech startups knock out thousands of genes at once to uncover which ones drive disease. They break down the difference between pooled and arrayed screens, walk through a real-world example from a startup hunting for combination therapies in ovarian cancer, and discuss the surprising finding
How Biotech Startups Use Patient Registries
In this episode of Biotech Business with Fexingo, Lucas and Luna dive into the world of patient registries — organized systems that collect real-world data from patients with specific conditions. They explore how startups are leveraging these registries to accelerate drug development, improve trial design, and even support regulatory approvals. Using the example of a rare disease registry, they br
How Biotech Startups Use AI to Repurpose Existing Drugs
In this episode of Biotech Business, Lucas and Luna explore the emerging field of AI-powered drug repurposing. They discuss how startups like Healx and Recursion are using machine learning to find new uses for existing drugs, dramatically cutting the time and cost of bringing treatments to patients. The conversation centers on a recent success story: a repurposed drug for a rare genetic disorder t
How Biotech Startups Use Liquid Biopsies to Find Cancer Early
Liquid biopsies are quietly transforming how we detect and monitor cancer — and biotech startups are at the center of it. In this episode, Lucas and Luna dig into the science and the business. They trace how a simple blood draw can catch tumor DNA months before symptoms appear, then follow a specific startup that's using methylation patterns to spot multiple cancer types at once. They break down w
How Biotech Startups Are Using Digital Twins
Digital twins — virtual replicas of physical systems — are moving from manufacturing and aerospace into biotech. In this episode, Lucas and Luna explore how startups are building digital twins of clinical trials, manufacturing lines, and even individual patients to cut costs and speed up development. They look at how a mid-stage biotech company used a digital twin of a Phase 3 trial to simulate di
How Biotech Startups Use Antibody-Drug Conjugates
In this episode of Biotech Business with Fexingo, Lucas and Luna explore how biotech startups are leveraging antibody-drug conjugates, or ADCs, to target cancer cells with precision. They break down the science behind ADCs, the business case for startups entering this space, and the challenges of manufacturing and safety. With real examples from the industry, they discuss why ADCs are becoming a h
How Biotech Startups Are Using In Vivo Gene Editing
In episode 155, Lucas and Luna explore the shift from ex vivo to in vivo gene editing, a frontier that could make one-time genetic therapies accessible beyond rare diseases. They break down the science behind lipid nanoparticle and viral vector delivery, the challenge of targeting the right cells, and the recent momentum signaled by FDA guidance. The conversation zooms in on a notable 2025 clinica
How Biotech Startups Use Organoids for Drug Testing
Organoids are miniature, lab-grown organs that mimic real human biology, and startups are using them to test drugs before they ever reach a human. In this episode, Lucas and Luna explore how these tiny 3D cultures are changing the game for disease modeling and drug screening. They discuss the scientific breakthroughs that make organoids possible, the challenges of making them reproducible at scale
How Biotech Startups Use Mass Spectrometry Imaging
In this episode of Biotech Business, Lucas and Luna explore how biotech startups are using mass spectrometry imaging to map drugs and metabolites directly inside tissue samples. They discuss the technology's shift from academic proteomics to pharmaceutical R&D, citing a recent startup that used it to identify why a promising oncology candidate failed in phase two, saving years of development. The
How Biotech Startups Use Phage Display for Targeted Therapies
In this episode of Biotech Business, Lucas and Luna explore how biotech startups are leveraging phage display to engineer antibodies and peptides for targeted therapies. They discuss the technology's origins, its role in drug discovery, and a recent case involving a startup that used phage display to create a bispecific antibody for cancer treatment. The hosts also touch on the challenges of scali
How Biotech Startups Use DNA Origami for Drug Delivery
In this episode of Biotech Business, Lucas and Luna explore a cutting-edge approach to drug delivery: DNA origami. They discuss how biotech startups are folding DNA strands into nanoscale structures to deliver therapies with unprecedented precision. The conversation centers on a recent proof-of-concept study where DNA origami boxes delivered a chemotherapy drug directly to cancer cells, reducing s
Biotech Startups Turn to Organ Chips for Drug Testing
In this milestone 150th episode of Biotech Business with Fexingo, Lucas and Luna explore how biotech startups are using organ-on-a-chip technology to test drugs before human trials. Centered on a concrete example — a startup using a lung-on-a-chip to model inflammation and test a candidate for chronic obstructive pulmonary disease — the conversation digs into the engineering, the regulatory shift
How Biotech Startups Use Nanopore Sequencing for Real-Time Genomics
In this episode of Biotech Business with Fexingo, Lucas and Luna explore how nanopore sequencing is giving biotech startups a real-time window into genomics. They dive into the technology's ability to read long DNA fragments on the fly, making it possible to detect pathogens, monitor outbreaks, and even sequence genomes in the field. The conversation centers on a specific application: using portab
How Biotech Startups Use AlphaFold for Drug Discovery
In this episode of Biotech Business with Fexingo, Lucas and Luna explore how biotech startups are leveraging AlphaFold, DeepMind's protein structure prediction AI, to accelerate drug discovery. They discuss the technology's evolution from a research curiosity to a practical tool, its role in tackling previously 'undruggable' targets, and the limitations that still require experimental validation.
How Biotech Startups Use PROTACs to Drug the Undruggable
Most disease-causing proteins have no obvious binding pocket, which is why roughly 80 percent of the human proteome has been considered 'undruggable' with traditional small molecules. In this episode, Lucas and Luna explore how biotech startups are tackling that problem with PROTACs — molecules that hijack the cell's own protein-disposal system to degrade targets rather than inhibit them. They tra
How Biotech Startups Reuse Orphan Drugs for Rare Diseases
In this episode of Biotech Business with Fexingo, Lucas and Luna explore how biotech startups are repurposing existing orphan drugs to treat rare diseases—a strategy that cuts development time and cost. They dive into the case of a small startup that took an approved therapy for a metabolic disorder and repositioned it for a rare neurological condition, leveraging FDA's orphan drug incentives. The
How Biotech Startups Use Synthetic Lethality Screens
In episode 145 of Biotech Business, Lucas and Luna explore how biotech startups are leveraging synthetic lethality screens to uncover new cancer drug targets. They anchor the discussion on the recent approval of a PARP inhibitor for pancreatic cancer, a milestone that validates the approach beyond BRCA-mutated tumors. The hosts walk through the science — how a mutation in one gene can be exploited
How Biotech Startups Use Single-Cell Sequencing
In this episode of Biotech Business with Fexingo, Lucas and Luna drill into single-cell RNA sequencing — the technology that lets researchers see gene expression in individual cells, not just tissue averages. They trace how a 2009 paper by a then-unknown Swedish scientist kicked off a field that now drives drug target discovery, patient stratification, and clinical trial design. Lucas explains the
Why Biotech Startups Are Turning to Proximity Labeling for Drug Discovery
In this episode of Biotech Business, Lucas and Luna explore how proximity labeling is becoming a go-to technique for biotech startups mapping protein interactions and finding new drug targets. They focus on the case of Turquoise Bio, a startup using the APEX2 enzyme to tag proteins in live cells in minutes—a method that captures transient interactions that older techniques miss. The hosts break do
How Biotech Startups Use AI to Design Better Clinical Trials
Episode 142 of Biotech Business with Fexingo dives into the quiet revolution in clinical trial design. Lucas and Luna explore how startups are using AI to simulate trial outcomes, optimize patient selection, and cut development timelines. They break down the story of a mid-stage oncology trial that used AI to reduce patient numbers by thirty percent without losing statistical power, and discuss th
How Biotech Startups Use Base Editing for Genetic Therapies
CRISPR made gene editing famous, but its blunt cuts carry risks. Base editing changes a single DNA letter without breaking the helix—a precision tool that startups like Beam Therapeutics and Verve Therapeutics are betting on for sickle cell disease and heart disease. This episode explains how base editing works, why it matters for patients, and the business challenges of turning a one-time edit in
How Biotech Startups Use Cryo-EM to Design Better Drugs
Cryo-electron microscopy, or cryo-EM, has transformed structural biology since winning the Nobel Prize in 2017. Once limited to academic labs with massive budgets, the technology is now within reach of biotech startups, enabling them to visualize proteins at atomic resolution and design drugs with unprecedented precision. In this episode, Lucas and Luna explore how one startup reduced a two-year t
How Real-World Evidence Is Changing Biotech Drug Approvals
This episode of Biotech Business with Fexingo explores how biotech startups are leveraging real-world evidence (RWE) to accelerate FDA approvals, especially for rare diseases. Lucas and Luna discuss the FDA's latest guidance on RWE, the types of data used (electronic health records, wearables, patient registries), and the advantages over traditional randomized controlled trials. They examine a cas
How Biotech Startups Are Engineering Antibodies to Cross the Blood-Brain Barrier
The blood-brain barrier (BBB) has long been the bane of CNS drug development, blocking over 98% of small molecules and virtually all large biologics. But in 2026, that wall is finally cracking. This episode examines how biotech startups like Denali Therapeutics are hijacking the brain's own transport systems—specifically the transferrin receptor—to shuttle antibodies and enzymes across the BBB. We
How Biotech Startups Use Exosomes for Drug Delivery
Exosomes, tiny vesicles that cells naturally secrete, are becoming a powerful drug delivery vehicle for biotech startups. This episode explores how companies like Evox Therapeutics and Codiak BioSciences are engineering exosomes to deliver RNA therapies, proteins, and small molecules to tissues that were previously hard to reach. We break down the science, the manufacturing challenges, and why big
Biotech Startups Target the Gut-Brain Axis for Depression
Episode 136 of Biotech Business explores how biotech startup Mendel Biotech is developing a live biotherapeutic for major depressive disorder. With promising Phase 2 data showing a 4-point reduction on the Hamilton Depression Rating Scale, we break down the gut-brain axis science, the challenges of manufacturing live bacterial therapies, and the regulatory path for FDA approval. We also discuss th
Recommended
The Daily
World News Tonight with David Muir
The Joe Rogan Experience
English Vocabulary Help
TED Talks Daily
Learn English B1 with Daily News | English Listening Practice
Talk About Talk - Executive & Leadership Communication Skills
English with Olivia | Slow Conversations & Vocabulary
Stand In The Circle
SLOW ENGLISH PODCAST (A1-A2) With Subtitles | Daily Videos | English With Us Podcast
Learn English A2 with Daily News | Simple English Listening Practice
پلی لیست | PlayList
